Identification of Type I Receptors for Osteogenic Protein-1 and Bone Morphogenetic Protein-4
Overview
Authors
Affiliations
Bone morphogenetic proteins (BMPs) are multifunctional proteins, structurally related to transforming growth factor-beta (TGF-beta) and activin. TGF-beta and activin exert their effects by forming heteromeric complexes of type I and type II serine/threonine kinase receptors. We have previously identified a series of type I serine/threonine kinase receptors, termed activin receptor-like kinase (ALK)-1 to -6. ALK-5 is a TGF-beta type I receptor, whereas ALK-2 and ALK-4 are activin type I receptors. Here we investigated the binding of proteins in the BMP family to ALKs. In transfected COS cells, the binding of osteogenic protein (OP)-1 and BMP-4 to certain ALKs was observed in the absence of type II receptors, and their binding was increased after co-transfection of a BMP type II receptor from Caenorhabditis elegans, DAF-4. OP-1 bound to ALK-2 and ALK-6 efficiently, and to ALK-3 less efficiently, whereas BMP-4 bound to ALK-3 and ALK-6 efficiently. Similarly, OP-1 bound to ALK-2, ALK-3, and/or ALK-6 in various nontransfected cell lines, although the binding profiles were different between different cell types. BMP-4 bound to ALK-3 in MC3T3-E1 osteoblasts and human foreskin fibroblasts. These results suggest that ALK-3 and ALK-6 are type I receptors for OP-1 and BMP-4; in addition, ALK-2 is a type I receptor shared by activin and OP-1, but not by BMP-4.
The BMP Signaling Pathway: Bridging Maternal-Fetal Crosstalk in Early Pregnancy.
Yang S, Gan J, Xu H, Shi J, Wang J, Zhang X Reprod Sci. 2025; .
PMID: 39821798 DOI: 10.1007/s43032-024-01777-4.
Webster N, Meyer N Neural Dev. 2024; 19(1):4.
PMID: 38698415 PMC: 11067212. DOI: 10.1186/s13064-024-00181-7.
Jiang F, Qin Y, Yang Y, Li Z, Cui B, Ju R Invest Ophthalmol Vis Sci. 2023; 64(4):12.
PMID: 37043340 PMC: 10103728. DOI: 10.1167/iovs.64.4.12.
Ganjoo S, Puebla-Osorio N, Nanez S, Hsu E, Voss T, Barsoumian H Front Immunol. 2022; 13:1033642.
PMID: 36353620 PMC: 9638036. DOI: 10.3389/fimmu.2022.1033642.
Takano M, Toda S, Watanabe H, Fujimura R, Nishida K, Bi J Pharmaceutics. 2022; 14(7).
PMID: 35890230 PMC: 9316787. DOI: 10.3390/pharmaceutics14071334.